Down’s syndrome with dementia
The antibody BAN2401, which is now being clinically evaluated for the treatment of Alzheimer’s disease, can potentially also be used for other indications such as Down’s syndrome with dementia, as most of these patients develop dementia pathology at around 40 years of age.
Traumatic brain injury (TBI)
BioArctic has submitted a patent application for the antibodies BAN2401/BAN2401 back-up for the treatment of Traumatic Brain Injury. Some of these patients develop dementia after the injury.